Shots:

• The filing is based on the results from the P-III IMpower010 study assessing Tecentriq (1200mg- IV) vs BSC in 1-005 patients in a ratio (1:1) with Stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
• Results: 34% reduction in risk of disease recurrence or death in people with PD-L1 expression compared with BSC while safety data were consistent with its known safety profile & no new safety signals were observed
• Additionally- ~50% of patients with early-stage lung cancer experience relapse following surgery. Tecentriq is the first cancer immunotherapy that showed efficacy for the adjuvant treatment of NSCLC

  Ref: Chugai | Image: Wikipedia